# Désirée van der Heijde

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/desiree-van-der-heijde/

## Facts

| Field | Value |
| --- | --- |
| Citations | 120,011 |
| Field | Rheumatoid Arthritis Research and Therapies |
| h-index | 160 |
| i10-index | 740 |
| Last Known Institution | Leiden University Medical Center |
| OpenAlex ID | https://openalex.org/A5104506506 |
| ORCID iD | https://orcid.org/0000-0002-5781-158X |
| Works | 1,353 |

## Researcher papers

Showing 12 of 16.

- [EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update](https://scholariq.org/papers/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic/)
- [Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis](https://scholariq.org/papers/infliximab-and-methotrexate-in-the-treatment-of-rheumatoid-arthritis/)
- [EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update](https://scholariq.org/papers/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic-2/)
- [EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update](https://scholariq.org/papers/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic-3/)
- [\nEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.](https://scholariq.org/papers/neular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic/)
- [Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force](https://scholariq.org/papers/treating-rheumatoid-arthritis-to-target-2014-update-of-the-recommendations-of-an/)
- [Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis](https://scholariq.org/papers/development-of-an-asas-endorsed-disease-activity-score-asdas-in-patients-with/)
- [Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis](https://scholariq.org/papers/baricitinib-versus-placebo-or-adalimumab-in-rheumatoid-arthritis/)
- [The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal](https://scholariq.org/papers/the-development-of-assessment-of-spondyloarthritis-international-society/)
- [European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update](https://scholariq.org/papers/european-league-against-rheumatism-eular-recommendations-for-the-management-of/)
- [EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis](https://scholariq.org/papers/eular-recommendations-for-the-use-of-imaging-of-the-joints-in-the-clinical/)
- [ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis](https://scholariq.org/papers/asdas-a-highly-discriminatory-asas-endorsed-disease-activity-score-in-patients/)

## Researcher topics

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Spine and Intervertebral Disc Pathology](https://scholariq.org/topics/spine-and-intervertebral-disc-pathology/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Autoimmune and Inflammatory Disorders Research](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders-research/)

## Researcher university

- [Leiden University Medical Center](https://scholariq.org/institutions/leiden-university-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.